Treatment of metastatic testicular carcinoma, according to prognosis;Behandeling van gemetastaseerd testiscarcinoom, naar prognose, en nieuwe ontwikkelingen

Nederlands Tijdschrift voor Geneeskunde

Volumn 145, Issue 25, 2001, Pages 1194-1199

  De Wit, R ^a   Stoter, G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE;

ARTICLE; CANCER CHEMOTHERAPY; METASTASIS; PROGNOSIS; TESTIS CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; EUROPE; GERMINOMA; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; UNITED STATES;

EID: 0035938913     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture
2. Treatment of testicular cancer: A new and improved model
3. Comparison of criteria for assigning germ cell tumor patients to 'good risk' and 'poor risk' studies
4. The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumours
5. The International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers
6. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide
7. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
8. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma
9. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial
10. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
11. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol
12. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council
13. Bleomycin in germ cell tumor therapy: Not all regimens are created equal
14. Rationale for the use of alternating non-cross-resistant chemotherapy
15. The genetic origin of drug resistance in neoplasms: Implications for systemic therapy
16. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: Comparison of commonly used classification systems of good and poor prognosis
17. Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime
18. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group
19. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol
20. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer
21. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study
22. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group
23. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: A Randomized Medical Research Council/European Organization for Research and Treatment of Cancer Study
24. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy
25. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors
26. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer
27. Management of intermediate-prognosis germ-cell cancer: Results of a phase I/II study of Taxol-BEP
28. Dose-intensive chemotherapy in refractory germ cell cancer - A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation
29. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support
30. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors
31. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial
32. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors